{"text": "包括ESRD患者在内的重度肾功能损害患者。", "spo_list": [{"object": {"@value": "肾功能损害"}, "object_type": {"@value": "Disease"}, "predicate": "Anatomy_Disease", "subject": "肾", "subject_type": "Anatomy"}]}
{"text": "该共识推荐采用胰岛素/口服药联合方案以增加降糖疗效，同时减少胰岛素治疗潜在的低血糖和体重增加的不良反应。二甲双胍与胰岛素联用可减少体重增加，减少外源性胰岛素用量；葡萄糖苷酶抑制剂与胰岛素联用在有效改善血糖的同时，可减少胰岛素用量，减少体重增加的幅度和趋势。因此，在无禁忌证的2型糖尿病患者中均可采用二甲双胍或糖苷酶抑制剂与胰岛素联用。", "spo_list": [{"object": {"@value": "胰岛素"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "低血糖", "subject_type": "ADE"}, {"object": {"@value": "胰岛素"}, "object_type": {"@value": "Drug"}, "predicate": "ADE_Drug", "subject": "体重增加", "subject_type": "ADE"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Class_Disease", "subject": "2型", "subject_type": "Class"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Drug_Disease", "subject": "二甲双胍", "subject_type": "Drug"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Drug_Disease", "subject": "糖苷酶抑制剂", "subject_type": "Drug"}, {"object": {"@value": "2型糖尿病"}, "object_type": {"@value": "Disease"}, "predicate": "Drug_Disease", "subject": "胰岛素", "subject_type": "Drug"}]}
{"text": "(2)持续皮下胰岛素输注", "spo_list": [{"object": {"@value": "胰岛素"}, "object_type": {"@value": "Drug"}, "predicate": "Method_Drug", "subject": "皮下", "subject_type": "Method"}]}
